Protagonist Therapeutics (PTGX) Long-Term Deferred Tax (2018 - 2020)
Protagonist Therapeutics (PTGX) posted Long-Term Deferred Tax of $1.1 million for Q1 2020, down 24.49% sequentially from $1.4 million in Q4 2019, and up 126.36% YoY from $478000.0 in Q2 2019.
Protagonist Therapeutics (PTGX) Long-Term Deferred Tax (2018 - 2020) Analysis & Trends
Protagonist Therapeutics has reported Long-Term Deferred Tax for 3 years, with the latest figure at $1.1 million in Q1 2020.
- Quarterly Long-Term Deferred Tax rose 126.36% year-over-year to $1.1 million in Q1 2020, while the trailing twelve-month figure through Mar 2020 was $1.1 million (up 126.36% YoY) and the FY2019 annual result came in at $1.4 million, up 117.78% from the prior year.
- Long-Term Deferred Tax retreated to $1.1 million in Q1 2020 per PTGX's latest filing, from $1.4 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $2.1 million in Q3 2019 and troughed at $478000.0 in Q1 2019.
- A 3-year average of $1.3 million and a median of $1.3 million in 2019 frame the typical range for Long-Term Deferred Tax.
- The sharpest annual moves came in 2019 and 2020: Long-Term Deferred Tax surged 117.78% in 2019, then soared 126.36% in 2020.
- Over 3 years, Long-Term Deferred Tax stood at $658000.0 in 2018, then soared by 117.78% to $1.4 million in 2019, then dropped by 24.49% to $1.1 million in 2020.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $1.1 million, $1.4 million, and $2.1 million for Q1 2020, Q4 2019, and Q3 2019 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 1.08 Mn |
| Dec 31, 2019 | 1.43 Mn |
| Sep 30, 2019 | 2.13 Mn |
| Jun 30, 2019 | 2.10 Mn |
| Mar 31, 2019 | 478,000.00 |
| Dec 31, 2018 | 658,000.00 |